Emerging evidence associates the use of isCGM with the reduction in diabetes-related events and all-cause hospitalizations in PwD following therapies with less intensive insulin regimen or glucose-lowering oral drugs [38,39]. This evidence concerns the gene INS and diabetes mellitus.